Repligen (NASDAQ:RGEN) Stock Rating Upgraded by Zacks Research

Repligen (NASDAQ:RGEN) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

RGEN has been the topic of several other research reports. Royal Bank Of Canada initiated coverage on shares of Repligen in a research report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective on the stock. Rothschild & Co Redburn set a $160.00 price target on shares of Repligen and gave the company a “buy” rating in a research report on Friday, April 17th. Wolfe Research assumed coverage on shares of Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target for the company. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research report on Tuesday, July 7th. Finally, Evercore reiterated an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a report on Monday, July 6th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average price target of $166.43.

Repligen Price Performance

Repligen stock opened at $141.01 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.05. Repligen has a 52-week low of $100.99 and a 52-week high of $175.77. The stock’s 50 day moving average price is $134.66 and its two-hundred day moving average price is $131.60. The stock has a market capitalization of $7.95 billion, a price-to-earnings ratio of 193.16, a PEG ratio of 2.67 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same quarter in the prior year, the company earned $0.26 earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities analysts predict that Repligen will post 2.06 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGEN. Wasatch Advisors LP grew its position in Repligen by 27.9% during the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after buying an additional 346,720 shares during the period. Handelsbanken Fonder AB increased its holdings in Repligen by 11.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 22,070 shares of the biotechnology company’s stock valued at $3,011,000 after acquiring an additional 2,332 shares during the last quarter. Everhart Financial Group Inc. purchased a new position in Repligen during the 2nd quarter valued at approximately $303,000. Assenagon Asset Management S.A. bought a new stake in Repligen in the second quarter worth $9,687,000. Finally, Balefire LLC purchased a new stake in shares of Repligen during the 2nd quarter valued at about $275,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.